Add To Watchlist
Share URL
About The Company
CEO
Dr. Henry H. Ji Ph.D.
Market Cap
7.44 Million USD
Sector
Healthcare
Website
https://www.sorrentotherapeutics.comLast Update
2/22/2024, 12:00:00 PM
Description
Sorrento Therapeutics, Inc.
Read More
Overview
Value
0
Growth
20
Health
33
Management
0
Analyst Opinion
69
Total
41
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative
- Has a high level of debt
- Altman-Z score suggests a risk of bankruptcy
- Disliked by Twitter users
- Poor earnings and cashflow growth
- Dividend could be at risk
Market Peers
SRNE
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
N/A
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Buy
Share Buybacks
N/A
Dividend Yeild (TTM)
8.48%
Valuation
Value Score
0
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 0.3 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-111.31%
PE/Earnings Growth
N/A
Price/Book
1.52x
Growth
Growth Score
20
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)
Revenue Growth
N/A
Earnings Growth
N/A
Cashflow Growth
N/A
Health
Health Score
33
Altman Z Score
0.00
Piostroski Score
3.00
Debt/Equity
3.02x
Current Assets/Liabilities
1.24x
Free Cashflow/Total Debt
0.00x
Debt/Capital
1.37x
Dividend
Secure Dividend Score
0
- ✔ Dividend yeild of 8.48% is more than the market average (1.85%)
- ✔ Long term dividend payout ratio of 0.00% is considered good
- ✔ Payout ratio (TTM) of -2.60% is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Very unsafe
Dividend Yeild
8.48%
Dividend Growth
N/A
Payout Ratio (Earnings)
-2.60%
Payout Ratio (Cashflow)
-7.62%
Management
Management Score
0
Average Buybacks/Dilution
N/A
Recent Buybacks/Dilution
85.86%
5 Year Price Volitility
25.29%
Return On Assets
-114.34%
Return On Capital Employed
-51.15%
Return On Equity
-1008.82%
Return On Free Cashflow
N/A
Return On Investments
-561.48%
Analysts
Analyst Opinion
69
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Sorrento Therapeutics, Inc.
Currency
USD
Beta
0
Vol Avg
36504129
Ceo
Dr. Henry H. Ji Ph.D.
Cik
0000850261
Cusip
83587F202
Exchange
NASDAQ Capital Market
Full Time Employees
799
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2007-01-19
Address
4955 Directors Place
City
San Diego
State
CA
Country
US
Zip
92121
Phone
858 203 4100
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
0
Twitter Sentiment
N/A
Stocktwits Sentiment
N/A